CY1124408T1 - ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ - Google Patents

ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ

Info

Publication number
CY1124408T1
CY1124408T1 CY20211100564T CY211100564T CY1124408T1 CY 1124408 T1 CY1124408 T1 CY 1124408T1 CY 20211100564 T CY20211100564 T CY 20211100564T CY 211100564 T CY211100564 T CY 211100564T CY 1124408 T1 CY1124408 T1 CY 1124408T1
Authority
CY
Cyprus
Prior art keywords
molecules
tgfβ inhibition
targeted
fragment
targeted tgfβ
Prior art date
Application number
CY20211100564T
Other languages
Greek (el)
English (en)
Inventor
Kin-Ming Lo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1124408T1 publication Critical patent/CY1124408T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
CY20211100564T 2014-02-10 2021-06-23 ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ CY1124408T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938048P 2014-02-10 2014-02-10
PCT/EP2015/052781 WO2015118175A2 (en) 2014-02-10 2015-02-10 TARGETED TGFβ INHIBITION

Publications (1)

Publication Number Publication Date
CY1124408T1 true CY1124408T1 (el) 2022-07-22

Family

ID=52988007

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100564T CY1124408T1 (el) 2014-02-10 2021-06-23 ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ

Country Status (28)

Country Link
US (4) US9676863B2 (enExample)
EP (2) EP3105246B1 (enExample)
JP (2) JP6731346B2 (enExample)
KR (1) KR102363008B1 (enExample)
CN (2) CN113549159A (enExample)
AU (3) AU2015213988B2 (enExample)
BR (1) BR112016014952A2 (enExample)
CA (1) CA2934979A1 (enExample)
CL (1) CL2016002017A1 (enExample)
CY (1) CY1124408T1 (enExample)
DK (2) DK3105246T3 (enExample)
ES (2) ES2992668T3 (enExample)
HR (1) HRP20210977T1 (enExample)
HU (1) HUE054873T2 (enExample)
IL (2) IL246968B (enExample)
LT (1) LT3105246T (enExample)
MX (2) MX381141B (enExample)
NZ (1) NZ721364A (enExample)
PE (2) PE20210168A1 (enExample)
PH (1) PH12016501549A1 (enExample)
PL (1) PL3105246T3 (enExample)
PT (1) PT3105246T (enExample)
RS (1) RS62038B1 (enExample)
RU (2) RU2021114500A (enExample)
SG (2) SG10202108879SA (enExample)
SI (1) SI3105246T1 (enExample)
SM (1) SMT202100542T1 (enExample)
WO (1) WO2015118175A2 (enExample)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
SG10202108879SA (en) 2014-02-10 2021-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
CA2994413A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
JP6933379B2 (ja) * 2015-09-24 2021-09-08 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 転移を低減するための方法および組成物
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
MX2018014047A (es) * 2016-05-17 2019-06-20 Genentech Inc Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
KR102366813B1 (ko) 2016-05-27 2022-02-24 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
KR20190039200A (ko) * 2016-08-12 2019-04-10 메르크 파텐트 게엠베하 암에 대한 조합 요법
KR102617453B1 (ko) 2016-09-19 2023-12-26 현대모비스 주식회사 보조 표지판 인식 장치 및 그 방법
WO2018064190A1 (en) 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
AU2018205233A1 (en) * 2017-01-07 2019-07-11 Merck Patent Gmbh Dosing regimens and dosage forms for targeted TGFβ inhibition
AU2018207281B2 (en) * 2017-01-10 2024-08-01 Precigen, Inc. Modulating expression of polypeptides via new gene switch expression systems
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
MA47265A (fr) 2017-01-13 2019-11-20 Agenus Inc Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers
EP3589663A4 (en) 2017-03-02 2020-10-21 National Research Council of Canada TGF-ß RECEPTOR ECTODOMAIN FUSION MOLECULES AND THEIR USES
EP3600410A1 (en) * 2017-03-30 2020-02-05 Merck Patent GmbH Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
DK3628049T3 (da) * 2017-05-04 2023-08-14 Acceleron Pharma Inc Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
US11440963B2 (en) 2017-05-09 2022-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
US11274142B2 (en) 2017-05-12 2022-03-15 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-β receptor and medicinal uses thereof
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
SG11202001319QA (en) 2017-09-04 2020-03-30 Agenus Inc T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
CN118652350A (zh) 2017-09-27 2024-09-17 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
MX2020004567A (es) * 2017-11-06 2020-08-13 Genentech Inc Metodos diagnosticos y terapeuticos para el cancer.
WO2019113464A1 (en) * 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US11692042B2 (en) 2018-03-09 2023-07-04 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
RU2020133020A (ru) 2018-03-14 2022-04-14 Мерк Патент Гмбх Соединения и их применения для лечения опухолей у субъекта
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
CN112218883A (zh) 2018-04-26 2021-01-12 艾吉纳斯公司 热休克蛋白结合肽组合物及其使用方法
JP2021522793A (ja) * 2018-05-03 2021-09-02 アクセルロン ファーマ インコーポレイテッド ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用
WO2019213446A1 (en) * 2018-05-03 2019-11-07 Acceleron Pharma Inc. NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
KR20210006405A (ko) 2018-05-04 2021-01-18 메르크 파텐트 게엠베하 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
SG11202011148VA (en) * 2018-05-15 2020-12-30 Merck Patent Gmbh Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
WO2019222676A1 (en) 2018-05-17 2019-11-21 Bolt Biotherapeutics, Inc. Immunoconjugates
EP3806842A4 (en) * 2018-06-13 2022-03-16 Merck Patent GmbH Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
WO2019242505A1 (zh) 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
CN112673020A (zh) * 2018-06-22 2021-04-16 默克专利有限公司 用于治疗胆道癌的靶向TGF-β抑制的给药方案
AU2019293047A1 (en) 2018-06-29 2021-01-28 Gensun Biopharma Inc. Antitumor immune checkpoint regulator antagonists
KR20210028219A (ko) * 2018-07-02 2021-03-11 메르크 파텐트 게엠베하 진행성 비소세포 폐암의 치료를 위한 표적화된 TGF-β 억제와의 조합 요법
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
KR20210042909A (ko) * 2018-07-09 2021-04-20 프레시전 인코포레이티드 융합 구조물 및 그의 이용 방법
WO2020041607A1 (en) * 2018-08-22 2020-02-27 Merck Patent Gmbh Treatment of triple negative breast cancer with targeted tgf-b inhibition
US20220242957A1 (en) 2018-09-27 2022-08-04 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
JP2022505925A (ja) 2018-11-01 2022-01-14 メルク パテント ゲーエムベーハー 抗ｔｉｍ－３抗体
CA3117371A1 (en) 2018-11-01 2020-05-07 Merck Patent Gmbh Methods of administering anti-tim-3 antibodies
AU2019374363A1 (en) 2018-11-09 2021-06-03 Jiangsu Hengrui Medicine Co., Ltd. TGF-β receptor fusion protein pharmaceutical composition and use thereof
CN113226335B (zh) * 2018-12-06 2023-10-13 广东天科雅生物医药科技有限公司 靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法
SG11202109033XA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020190734A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting pd-l1
WO2020248926A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗PDL1和TGFβ的双功能融合蛋白及其用途
KR20220034784A (ko) 2019-06-13 2022-03-18 볼트 바이오테라퓨틱스 인코퍼레이티드 아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도
CN110218260A (zh) * 2019-06-24 2019-09-10 王跃驹 植物作为宿主在表达m7842中的应用
EP3990116A1 (en) * 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2021007428A2 (en) * 2019-07-09 2021-01-14 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer
CN112239507A (zh) * 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
CA3149810A1 (en) * 2019-08-15 2021-02-18 Nantbio, Inc. Tgf-beta trap
CN118126195A (zh) * 2019-08-30 2024-06-04 正大天晴药业集团南京顺欣制药有限公司 一种靶向PD-L1和TGF-β的融合蛋白及其用途
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
CA3148694A1 (en) 2019-09-03 2021-03-11 Romas Kudirka Aminoquinoline compounds, immunoconjugates, and uses thereof
JP2022547066A (ja) 2019-09-04 2022-11-10 ボルト バイオセラピューティクス、インコーポレーテッド 免疫結合体合成方法
CN112442132A (zh) * 2019-09-05 2021-03-05 复旦大学 靶向肿瘤的重组双功能融合蛋白及其应用
CN115947846A (zh) 2019-09-12 2023-04-11 普米斯生物技术(珠海)有限公司 一种抗pd-l1纳米抗体及其衍生物和用途
KR20220071264A (ko) * 2019-09-30 2022-05-31 하버 바이오메드 (상하이) 컴퍼니 리미티드 항-pd-l1 항원 결합 단백질 및 이의 응용
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
US11802145B2 (en) 2019-10-21 2023-10-31 Nanjing Leads Biolabs Co., Ltd. Recombinant protein targeting PD-1 and TGFß
KR20220088901A (ko) 2019-10-25 2022-06-28 볼트 바이오테라퓨틱스 인코퍼레이티드 티에노아제핀 면역접합체, 및 이의 용도
JP2023501971A (ja) * 2019-11-01 2023-01-20 アレス トレーディング ソシエテ アノニム 癌の治療のための、放射線療法と共に用いるＰＤ－１、ＴＧＦβ、及びＡＴＭの組み合わせ阻害
US20230340122A1 (en) 2019-11-05 2023-10-26 Glaxosmithkline Intellectual Property (No. 4) Ltd. Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
WO2021093760A1 (zh) * 2019-11-12 2021-05-20 江苏恒瑞医药股份有限公司 含有TGF-β受体的融合蛋白及其医药用途
US20230242675A1 (en) * 2019-11-27 2023-08-03 Shanghai Epimab Biotherapeutics Co., Ltd. TGF[beta]/PD-L1 BISPECIFIC BINDING PROTEINS
CN115996955A (zh) * 2019-12-11 2023-04-21 上海药明生物技术有限公司 针对PD-L1和TGFβ的双功能抗体
CN113004414B (zh) * 2019-12-20 2022-09-06 广东菲鹏制药股份有限公司 抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
EP4076388A1 (en) 2019-12-20 2022-10-26 Ares Trading S.A. Igg:tgfbetarii fusion protein composition
EP3838260A1 (en) 2019-12-20 2021-06-23 Ares Trading S.A. Igg:tgf rii fusion protein composition
CN113121699A (zh) * 2019-12-30 2021-07-16 国典(北京)医药科技有限公司 Pttrap1双特异性融合蛋白及其应用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CA3162009A1 (en) * 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag New 4-1bbl trimer-containing antigen binding molecules
JP2023511363A (ja) * 2020-01-21 2023-03-17 ボルト バイオセラピューティクス、インコーポレーテッド 坑ｐｄ－ｌ１抗体
EP4093510A1 (en) * 2020-01-21 2022-11-30 Bolt Biotherapeutics, Inc. Anti-pd-l1 antibodies
US20230093512A1 (en) * 2020-02-18 2023-03-23 Nanjing GenScript Biotech Co., Ltd. Fusion proteins and uses thereof
CN115175942B (zh) * 2020-02-25 2025-05-30 上海药明生物技术有限公司 一种双功能融合蛋白及其用途
TW202136315A (zh) * 2020-03-20 2021-10-01 大陸商榮昌生物製藥（煙臺）股份有限公司 一種雙特異性融合蛋白及其應用
JP2023521465A (ja) 2020-04-14 2023-05-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ＩＣＯＳ抗体とＰＤ－Ｌ１抗体ＴＧＦ－β－受容体融合タンパク質とに基づく癌の併用治療
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
EP4139363A4 (en) 2020-04-24 2024-09-04 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP2023523480A (ja) 2020-04-28 2023-06-06 ザ ロックフェラー ユニバーシティー 中和抗ｓａｒｓ－ｃｏｖ－２抗体およびその使用方法
BR112022022020A2 (pt) * 2020-04-29 2023-01-31 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteína bifuncional contra pd-1 e tgf-ss
CN115461122A (zh) 2020-05-01 2022-12-09 博尔特生物治疗药物有限公司 抗dectin-2抗体
EP4146282A1 (en) 2020-05-08 2023-03-15 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
IL299289A (en) * 2020-06-26 2023-02-01 Sorrento Therapeutics Inc Oncolytic herpes simplex viruses (HSV) expressing immunomodulatory proteins
CA3188596A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
EP4194002A4 (en) * 2020-07-24 2024-08-14 Mabwell (Shanghai) Bioscience Co., Ltd. TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN
WO2022022503A1 (en) * 2020-07-28 2022-02-03 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting pd-l1 and tgf-beta
US11028174B1 (en) 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
TW202214287A (zh) * 2020-08-24 2022-04-16 大陸商江蘇恒瑞醫藥股份有限公司 TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
CA3190766A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
EP4204450A4 (en) 2020-08-26 2024-11-13 Marengo Therapeutics, Inc. MULTIFUNCTIONAL CALRETICULIN-BINDING MOLECULES AND RELATED USES
JP2023540248A (ja) 2020-08-26 2023-09-22 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法
CN115884989A (zh) * 2020-08-31 2023-03-31 杭州九源基因工程有限公司 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
CN114106190B (zh) 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
CN117157314A (zh) * 2020-09-16 2023-12-01 苏州逻晟生物医药有限公司 Pd-l1抗体、融合蛋白及其用途
WO2022057061A1 (en) * 2020-09-16 2022-03-24 Suzhou Neologics Bioscience Co., Ltd. Pd-l1 antibodies, fusion proteins, and uses thereof
TWI815184B (zh) * 2020-09-23 2023-09-11 大陸商海正生物製藥有限公司 Tgfbr2-ecd突變體及包含其的融合蛋白與應用
CN116323657B (zh) * 2020-09-24 2023-12-08 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN114349867B (zh) * 2020-10-14 2024-05-28 广东菲鹏制药股份有限公司 融合蛋白及其应用
JP2023550900A (ja) 2020-11-02 2023-12-06 アレス トレーディング ソシエテ アノニム がんの組み合わせ治療
CN116801906A (zh) 2020-11-02 2023-09-22 阿雷斯贸易股份有限公司 癌症的联合治疗
CN114573701A (zh) * 2020-12-02 2022-06-03 上海华奥泰生物药业股份有限公司 抗PD-L1/TGF-β双功能抗体及其用途
IL303491A (en) 2020-12-11 2023-08-01 Bolt Biotherapeutics Inc Anti-pd-l1 immunoconjugates, and uses thereof
US20240238430A1 (en) 2020-12-11 2024-07-18 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
CN116917334A (zh) 2021-02-22 2023-10-20 浙江道尔生物科技有限公司 一种具有抗癌活性的多结构域融合蛋白
AU2022230795B2 (en) 2021-03-02 2025-02-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
EP4313162A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CA3212907A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
WO2022233718A2 (en) 2021-05-03 2022-11-10 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
CN114773485B (zh) * 2021-05-11 2024-05-17 江苏先声药业有限公司 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
IL308818A (en) 2021-05-25 2024-01-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
WO2022258622A1 (en) 2021-06-07 2022-12-15 Ares Trading S.A. Combination treatment of cancer
JP2024534263A (ja) * 2021-08-27 2024-09-18 セラノティックス カンパニー リミテッド Ｂ７－Ｈ３及びＴＧＦβに特異的に結合する二重特異性分子、並びにその用途
AU2023210700A1 (en) 2022-01-28 2024-08-15 35Pharma Inc. Activin receptor type iib variants and uses thereof
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
WO2023221936A1 (zh) 2022-05-17 2023-11-23 苏州创胜医药集团有限公司 双功能蛋白质及其制剂和用途
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024216089A1 (en) 2023-04-13 2024-10-17 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibody combination therapy
US20250136663A1 (en) * 2023-10-31 2025-05-01 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
KR20250078792A (ko) * 2023-11-24 2025-06-04 주식회사 메드팩토 피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
WO2025140212A1 (en) * 2023-12-26 2025-07-03 Laekna Therapeutics Shanghai Co., Ltd. Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
EP4653010A1 (en) 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
DK0975771T3 (da) * 1997-04-18 2007-10-22 Biogen Idec Inc Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP2005112812A (ja) * 2003-10-09 2005-04-28 Zeria Pharmaceut Co Ltd リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
KR20070007055A (ko) * 2003-12-24 2007-01-12 사이오스 인코퍼레이티드 Ｔｇｆ-베타 억제제를 이용한 악성 신경교종의 치료법
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
WO2008157367A1 (en) 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US20140127200A1 (en) 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
MX2011000039A (es) 2008-07-02 2011-05-31 Emergent Product Dev Seattle Proteinas antagonistas del factor-beta de crecimiento transformante (tgf-beta), que se unen a multiples objetivos.
KR20250091300A (ko) * 2008-12-09 2025-06-20 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
DK2504364T3 (da) 2009-11-24 2017-11-06 Medimmune Ltd Målrettede bindemidler mod b7-h1
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
WO2011090762A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
KR20180028561A (ko) 2010-02-23 2018-03-16 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
WO2011109789A2 (en) * 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
AR087405A1 (es) * 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
SMT202000561T1 (it) 2011-11-28 2021-01-05 Merck Patent Gmbh Anticorpi anti-pd-l1 e usi relativi
NZ714549A (en) * 2012-04-30 2016-10-28 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
WO2014193898A1 (en) 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SG10202108879SA (en) 2014-02-10 2021-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6764858B2 (ja) 2014-08-15 2020-10-07 メルク パテント ゲーエムベーハー Ｓｉｒｐ−アルファ免疫グロブリン融合タンパク質

Also Published As

Publication number Publication date
KR20160119197A (ko) 2016-10-12
IL281565A (en) 2021-05-31
HRP20210977T1 (hr) 2021-09-17
CN113549159A (zh) 2021-10-26
SG10202108879SA (en) 2021-09-29
MX2021003685A (es) 2021-06-04
RU2016135062A3 (enExample) 2018-12-12
ES2876430T3 (es) 2021-11-12
US9676863B2 (en) 2017-06-13
DK3105246T3 (da) 2021-06-14
PL3105246T3 (pl) 2021-11-29
PH12016501549A1 (en) 2016-10-03
EP3105246B1 (en) 2021-03-31
US11370819B2 (en) 2022-06-28
US20230056881A1 (en) 2023-02-23
EP3889172B1 (en) 2024-05-01
US20200055949A1 (en) 2020-02-20
BR112016014952A2 (pt) 2017-09-19
MX381141B (es) 2025-03-12
MX2016010067A (es) 2016-10-07
CA2934979A1 (en) 2015-08-13
IL246968B (en) 2021-04-29
SG11201606577YA (en) 2016-09-29
WO2015118175A2 (en) 2015-08-13
DK3889172T3 (da) 2024-06-17
AU2015213988B2 (en) 2019-07-11
AU2019246876A1 (en) 2019-10-31
PE20161096A1 (es) 2016-10-22
PT3105246T (pt) 2021-06-28
SMT202100542T1 (it) 2021-11-12
RU2021114500A (ru) 2021-06-07
AU2022200365A1 (en) 2022-02-17
SI3105246T1 (sl) 2021-11-30
KR102363008B1 (ko) 2022-02-16
CN106103488A (zh) 2016-11-09
LT3105246T (lt) 2021-08-25
PE20210168A1 (es) 2021-01-28
RS62038B1 (sr) 2021-07-30
AU2019246876B2 (en) 2021-10-21
AU2015213988A1 (en) 2016-07-07
CL2016002017A1 (es) 2017-06-09
HUE054873T2 (hu) 2021-10-28
JP2017506217A (ja) 2017-03-02
NZ721364A (en) 2023-04-28
EP3889172A1 (en) 2021-10-06
EP3105246A2 (en) 2016-12-21
CN106103488B (zh) 2021-07-30
RU2016135062A (ru) 2018-03-15
IL281565B (en) 2021-12-01
JP2020174674A (ja) 2020-10-29
JP6731346B2 (ja) 2020-07-29
US20150225483A1 (en) 2015-08-13
RU2752424C2 (ru) 2021-07-28
IL246968A0 (en) 2016-09-29
US20180002436A1 (en) 2018-01-04
ES2992668T3 (en) 2024-12-16
WO2015118175A3 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
CY1124408T1 (el) ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ
CY1125440T1 (el) Αντι-τιμ-3 αντισωματα και συνθεσεις
CY1124299T1 (el) Συνδυαστικες θεραπειες που περιλαμβανουν μορια αντισωματων κατα toy lag-3
CY1125327T1 (el) Anti-pd-1 αντισωματα και συνθεσεις
CY1124437T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1125011T1 (el) Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1124619T1 (el) Αντισωματα αντι-προ/λανθανουσας μυοστατινης και χρησεις αυτων
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA202091540A1 (ru) Антитела к lilrb2
PH12019500270A1 (en) Combination therapy for cancer
MY195474A (en) Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
PH12017500890A1 (en) Antibody drug conjugates
BR112017000497A2 (pt) ?anticorpos anti pd-l1 e usos de diagnóstico dos mesmos?
MX373019B (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antígeno 4 de linfocito t citotóxico (anti-ctla-4).
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
CY1122678T1 (el) Μορια συνδεσης προσδετη και χρησεις αυτων